SmartAnalyst
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $240k | Series A | |
N/A | $790k | Series B | |
$3.8m | Series C | ||
$2.0m | Series D | ||
N/A | $1.2m | Series E | |
$320k | Late VC | ||
$24.0m Valuation: $24.0m | Acquisition | ||
Total Funding | €7.6m |
Related Content
Recent News about SmartAnalyst
EditSmartAnalyst is a strategic consulting firm specializing in providing decision analysis solutions for the pharmaceutical and biotech industries. The company serves a diverse range of clients, including over 100 pharma and biotech companies, with 17 of the top 20 global pharma companies among them. Operating in the life sciences market, SmartAnalyst offers services such as Health Economics and Outcomes Research (HEOR), Real World Evidence (RWE), and specialized insights series in oncology, immunology, and rare diseases. The business model revolves around delivering high-value strategic insights that help clients bridge the gap between research and development (R&D) and commercial success. Revenue is generated through consulting fees and subscription-based insights solutions.
Keywords: strategic consulting, pharma, biotech, HEOR, RWE, oncology, immunology, rare diseases, pipeline value, portfolio management.